NThe points I have noted previously in a hypothetical case for cf33 lacking efficacy are:
1. producing no further objective responses beyond first three depsite 47 patients dosed at last update.
2. recruitment seemingly slowing down massively.
Evidence for one side, so far not much for the other.
All hypothetical of course.
Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-124
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.001(2.08%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 4.9¢ | 4.8¢ | $179.8K | 3.692M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 8124186 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3070575 | 9 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |